A detailed history of Prelude Capital Management, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Prelude Capital Management, LLC holds 15,595 shares of IONS stock, worth $496,076. This represents 0.04% of its overall portfolio holdings.

Number of Shares
15,595
Holding current value
$496,076
% of portfolio
0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$33.73 - $40.36 $526,019 - $629,414
15,595 New
15,595 $545,000
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $76,258 - $101,553
-2,087 Reduced 28.1%
5,341 $236,000
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $235,541 - $319,404
7,428 New
7,428 $275,000
Q4 2020

Feb 16, 2021

SELL
$45.3 - $60.27 $7,610 - $10,125
-168 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$47.45 - $62.95 $59,122 - $78,435
-1,246 Reduced 88.12%
168 $8,000
Q2 2020

Aug 14, 2020

BUY
$46.85 - $61.05 $66,245 - $86,324
1,414 New
1,414 $83,000
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $5,815 - $7,049
-108 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$59.06 - $72.15 $6,378 - $7,792
108 New
108 $6,000
Q2 2019

Aug 14, 2019

SELL
$62.09 - $86.14 $67,491 - $93,634
-1,087 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$52.92 - $81.17 $36,620 - $56,169
692 Added 175.19%
1,087 $88,000
Q4 2018

Feb 14, 2019

SELL
$43.37 - $59.54 $684,335 - $939,481
-15,779 Reduced 97.56%
395 $21,000
Q3 2018

Nov 14, 2018

BUY
$42.88 - $53.7 $693,541 - $868,543
16,174 New
16,174 $834,000
Q1 2018

May 15, 2018

SELL
$44.08 - $55.05 $15,428 - $19,267
-350 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$50.3 - $64.39 $1.61 Million - $2.06 Million
-31,979 Reduced 98.92%
350 $18,000
Q3 2017

Nov 14, 2017

BUY
$45.56 - $59.57 $1.47 Million - $1.93 Million
32,329
32,329 $1.64 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.52B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.